Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.55 |
| ▸ | FABP6 | P51161 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11306424 | 0.88 | ALDH1A1 (0.54) | ABL1FABP6ALDH1A1HPGDRAB9A | |
| SCHEMBL28165968 | 0.85 | TDP1 (0.46) | CHEK2ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30732472 | 0.85 | CHEK2 (0.47) | CHEK2MAPT | |
| SCHEMBL416899 | 0.82 | ABL1 (0.78) | ABL1FABP6CHEK2ALDH1A1HPGD | |
| SCHEMBL19994450 | 0.81 | CHEK2 (0.75) | CHEK2MEN1KMT2A | |
| Bromide SCHEMBL16324631 | 0.81 | ABL1 (0.76) | ABL1FABP6CHEK2ALDH1A1HPGD | |
| SCHEMBL8954976 | 0.80 | ABL1 (0.51) | ABL1FABP6CHEK2ALDH1A1HPGD | |
| SCHEMBL1380709 | 0.80 | CHEK2 (0.81) | CHEK2 | |
| SCHEMBL14432750 | 0.79 | CHEK2 (0.50) | ABL1CHEK2 | |
| SCHEMBL10466050 | 0.79 | ALDH1A1 (0.54) | ABL1FABP6CHEK2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7601745-B2 | Heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20080241100-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYTOKINE | 4SC AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | ABL1 957/4885FABP6 3867/4885CHEK2 1382/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | ABL1 1214/4885FABP6 3869/4885CHEK2 617/4885 |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | ABL1 1877/4885FABP6 3983/4885CHEK2 1429/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | ABL1 957/4885FABP6 3867/4885CHEK2 1382/4885 |
| US-20080241100-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYTOKINE | IL2, IL17A, IFNG | ABL1 2448/4885FABP6 1613/4885CHEK2 4213/4885 |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, IKBKB, NFKB2 | ABL1 1204/4885FABP6 3853/4885CHEK2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.